

Study of Adiponectin as an Inflammatory Biomarker in Patients with Chronic Obstructive Pulmonary Disease

Thesis

*Submitted in Partial Fulfillment of the Master Degree
in Chest Diseases*

Presented by

Ahmad Kamal Elsayed Gedamy
(M.B., B.Ch.)

Under supervision of

Prof. Samiha Sayed Ahmad Ashmawi

Professor of Chest Diseases
Faculty of Medicine, Ain Shams University


Dr. Tamer Mohamad Ali

Assistant Professor of Chest Diseases
Faculty of Medicine, Ain Shams University

Dr. Amira Ibrahim Hamed

Assistant Professor of Clinical Pathology
Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain-Shams University
2014**



(-)

ACKNOWLEDGEMENT

First of all, I would like to express my prayerful thanks to **Allah** for everything.

Great people contributed to this work particularly that is owed to my advisors **Prof. Samiha Sayed Ahmad Ashmawi**, Professor of Chest Diseases and Tuberculosis, Faculty of Medicine, Ain Shams University, for her valuable experience and unlimited guidance and encouragement.

I am also deeply impressed and wish to express my heartfelt thanks to **Dr. Tamer Mohamad Ali**, Assistant Professor of Chest Diseases and Tuberculosis, Faculty of Medicine, Ain Shams University, for his assistance and follow up of the progress of this work with keen and interest.

All my thanks to **Dr. Amira Ibrahim Hamed**, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her great valuable efforts in completing this research.

I would like to thank the patients included in this study and I wish to them optimal health and happiness. Finally I wish to thank my colleagues, friends and family for their contributions and support.

Ahmad kamal Elsayed Gedamy

List of Contents

Title	Page
• List of Tables	I
• List of Figures.....	III
• List of Abbreviations.....	V
• Introduction	1
• Aim of the Work	3
• Review of Literature:	
○ Chronic Obstructive Pulmonary Disease (COPD)	4
○ Adiponectin	66
• Subjects and Methods	85
• Results	94
• Discussion.....	112
• Summary	119
• Conclusion	123
• Recommendations	124
• References	125
• Arabic Summary	--

List of Tables

Table No.	Title	Page
Table (1):	Staging of COPD.....	5
Table (2):	Staging of COPD.....	6
Table (3):	Differential Diagnosis of COPD.....	34
Table (4):	Clinical history, physical findings and diagnostic procedures in patients with exacerbation of chronic obstructive pulmonary disease (COPD).....	56
Table (5):	Description of personal and clinical characteristics of Stable COPD group.....	94
Table (6):	Description of PFT and adiponectin among stable COPD group.....	94
Table (7):	Description of personal and clinical characteristics of AE COPD group	95
Table (8):	Description of PFT and adiponectin among AE COPD group.....	95
Table (9):	Description of personal and clinical characteristics of Control group	96
Table (10):	Description of PFT and adiponectin among control group	96
Table (11):	Statistical comparison of the age among studied groups	97
Table (12):	Statistical comparison of the FEV1/FVC and FEV1 among COPD during exacerbation and in stable states	98
Table (13):	Statistical comparison of the FEV1/FVC and FEV1 among COPD during exacerbation and in control group	99
Table (14):	Statistical comparison of the FEV1/FVC and FEV1 among COPD in stable states and in control group.....	101

List of Tables (Cont.)

Table No.	Title	Page
Table (15):	Statistical comparison of serum adiponectin (mcg/ml) between COPD cases during exacerbation in comparison with the control group.....	102
Table (16):	Statistical comparison of serum adiponectin (mcg/ml) between COPD cases in stable states in comparison with the control group.....	103
Table (17):	Statistical comparison of serum adiponectin (mcg/ml) between COPD cases during exacerbation and during stable states.....	104
Table (18):	Statistical comparison of serum adiponectin (mcg/ml) between mild, moderate and severe grade of stable COPD cases	105
Table (19):	Correlation between changes in serum adiponectin (mcg/ml) and changes in FEV1 (% pred) and FEV1/FVC in COPD cases in exacerbation.....	106
Table (20):	Correlation between changes in serum adiponectin (mcg/ml) and changes in FEV1 (% pred) and FEV1/FVC in stable COPD cases	108
Table (21):	Correlation between smoking index and serum adiponectin (mcg/ml) in acute exacerbation COPD cases	110
Table (22):	Correlation between smoking index and serum adiponectin (mcg/ml) in stable COPD cases	111

List of Figures

Figure No.	Title	Page
Figure (1):	Pathogenesis of COPD	22
Figure (2):	Chronic Obstructive Pulmonary Disease; FEV 1: Forced Expiratory Volume in first second; FVC: Forced Vital Capacity	32
Figure (3):	Pharmacologic Therapy by Disease Severity	46
Figure (4):	The Cycle of Physical, Social, and Psychosocial	47
Figure (5):	Algorithm for the Management of an Exacerbation of COPD at Home	59
Figure (6):	Adiponectin hormone molecule	68
Figure (7):	Metabolic effects of Adiponectin	72
Figure (8):	Statistical comparison of the age among studied groups	97
Figure (9):	Statistical comparison of the FEV1/FVC and FEV1 among COPD during exacerbation and in stable states	98
Figure (10):	Statistical comparison of the FEV1/FVC and FEV1 among COPD during exacerbation and in control group	100
Figure (11):	Statistical comparison of the FEV1/FVC and FEV1 among COPD in stable states and in control group	101
Figure (12):	Statistical comparison of serum adiponectin (mcg/ml) between COPD cases during exacerbation in comparison with the control group	102
Figure (13):	Statistical comparison of serum adiponectin (mcg/ml) between COPD cases in stable states in comparison with the control group	103

List of Figures (Cont.)

Figure No.	Title	Page
Figure (14):	Statistical comparison of serum adiponectin (mcg/ml) between COPD cases during exacerbation and during stable states	104
Figure (15):	Statistical comparison of serum adiponectin (mcg/ml) between mild, moderate and severe grade of stable COPD cases.....	105
Figure (16):	Correlation between changes in serum adiponectin (mcg/ml) and changes in FEV1 (% pred) in COPD cases during exacerbation.....	106
Figure (17):	Correlation between changes in serum adiponectin (mcg/ml) and changes in FEV1/FVC in COPD cases during exacerbation	107
Figure (18):	Correlation between changes in serum adiponectin (mcg/ml) and changes in FEV1 (% pred) in stable COPD cases.....	108
Figure (19):	Correlation between changes in serum adiponectin (mcg/ml) and changes in FEV1/FVC in stable COPD cases.....	109
Figure (20):	Correlation between smoking index and serum adiponectin (mcg/ml) in COPD cases during exacerbation.....	110
Figure (21):	Correlation between smoking index and serum adiponectin (mcg/ml) in stable COPD cases.....	111

List of Abbreviations

ADIPOR1	Adiponectin receptor 1
ADIPOR2	Adiponectin receptor 2
AECOPD	Acute exacerbation of chronic obstructive pulmonary disease
APN	Adiponectin
ASP	Acylation stimulating protein
BMD	Bone mineral density
BMI	Body mass index
BODE	Body mass index, obstruction, dyspnea and exercise
CAD	Coronary artery disease
COPD	Chronic obstructive pulmonary disease
CRP	C-reactive protein
CT	Computed tomography
CVD	Cardio vascular disease
DALYs	Disability- Adjusted Life Years
DLCO	Diffusion capacity of the lung to carbon monoxide
ECG	Electrocardiogram
ESR	Erythrocyte sedimentation rate
ETS	Environmental tobacco smoke
Fcγ	Crystallisable fragments gamma
FEV1	Forced expiratory volume in first second

List of Abbreviations (Cont.)

FFM	Fat free mass
F-Vloop	Flow volume loop
FVC	Forced vital capacity
HIV	Human immune deficiency virus
HRCT	High resolution computed tomography
ICS	Inhaled corticosteroid
ICU	Intensive care unit
IHD	Ischemic heart diseases
IL-1	Interleukin-1
IL-10	Interleukin-10
IL-6	Interleukin-6
IL-8	Interleukin-8
INF-γ	Interferon gamma
LBP	Lipopolysaccharide binding protein
LDL	Low density lipoprotein
LPL	Lipoprotein lipase
LVRS	Lung volume reduction surgery
MDI	Metered dose inhaler
mEPHX1	Microsomal epoxide hydrolase 1
MMP	Matrix metalloproteinases
MVV	Maximal voluntary ventilation

List of Abbreviations (Cont.)

NAFLD	Non-alcoholic fatty liver diseases
NF-κB	Nuclear factor kappa beta
NICE	National Institute for Clinical Excellence
NPPV	Non invasive positive pressure ventilation
PAI-1	Plasminogen activator inhibitor- 1
PaCO₂	Partial pressure of carbon dioxide in arterial blood
PaO₂	Partial pressure of oxygen in arterial blood
PCT	Procalcitonin
PDE4	Phosphodiesterase 4
PEF	Peak expiratory flow
REE	Resting energy expenditure
SaO₂	Oxygen saturation in arterial blood
T-cad	T-cadherin
TGF-β1	Transforming growth factor beta-1
TLC	Total lung capacity
TNF-α	Tumor necrosis factor alpha
VLDL	Very low density lipoprotein
WC	Waist circumference
YLD	Years of living with disability